It is specifically approved by the FDA for chronic weight management in adults with a body mass index (BMI) of 30 kg/m or greater or a BMI of 27 kg/m or greater with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol
Rising global prevalence of obesity and type 2 diabetes is a primary growth driver for the market
Angiopoietin-like 4 is a wnt signaling antagonist that promotes LRP6 turnover
The Precision Peptide test also evaluates FTO and MC4R variants that influence satiety signaling and appetite regulation independent of injection location
Fortunately, this modification is reversible through the action of glutaredoxin (Grx1), which interacts closely with eNOS (Chen et al., 2013)
Braslis KG and Costello AJ: Corporeal penile plication for correction of erectile penile deformity